GALNT7 and prostate carcinoma: Next, we validated DBNDD1 expression in GSE220942 (the role of GALNT7 upregulation in PCa cells) and GSE217260 (DEGs of benign prostatic hyperplasia and high-risk prostatic carcinoma tissues).